10/07/26 -"Europe approves genome editing for crop improvement. This means a historical milestone and KWS should structurally benefit mid-term. Add, TP EUR 78 confirmed"
10/07/26 -"Europe approves genome editing for crop improvement. This means a historical milestone and KWS should structurally benefit mid-term. Add, TP EUR 78 confirmed"
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
| Corporate broking | NO |
| Trading in corporate shares | NO |
| Analyst ownership | NO |
| Advising of corporate (strategy, marketing, debt, etc) | NO |
| Research paid for by corporate | NO |
| Provision of corporate access paid for by corporate | NO |
| Link between and a banking entity | NO |
| Brokerage activity at AlphaValue | NO |